Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

26/05/2016
MSF calls on G7 leaders to urgently address the critical gaps in global response to public health emergencies and unite to lower the price of live-saving medicines

Ise-Shima, Japan/Geneva May 26, 2016 - Two years since the first signs of the West Africa Ebola outbreak, the world today is little more prepared to respond to such an emergency than it was then, warns international humanitarian aid organisation Médecins Sans Frontières (MSF), while the lack of R&D into needed medicines and exorbitant medicine...

Read more...





26/05/2016
Cipla gets approval to sell its version of Truvada PrEP in India

First company to get DCGI approval for HIV prevention drug Mumbai, May 23: Drugmaker Cipla has received regulatory approval in India to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV. Commonly referred to as PrEP (pre-exposure prophylaxis) in healthcare circles, Truvada, sold by US drugmaker Gilead,...

Read more...

Source Source: BusinessLine

Tags: PrEP




26/05/2016
The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals?

Abstract Background and Aims The advent of highly effective hepatitis C (HCV) treatments has questioned the need for a vaccine to control HCV amongst people who inject drugs (PWID). However, high treatment costs and ongoing reinfection risk suggest it could still play a role. We compared the impact of HCV vaccination amongst PWID against providing HCV treatment....

Read more...

Source Source: PLOS ONE





26/05/2016
FDA approves first buprenorphine implant for treatment of opioid dependence

Expanded use and availability of medication-assisted treatment is a top priority of federal effort to combat opioid epidemic May 26, 2016 - The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in...

Read more...

Source Source: FDA





26/05/2016
DDW 2016: Shorter course of ledipasvir/sofosbuvir therapy effective in patients with genotype 1 hepatitis C

“This comparative analysis was conducted to determine whether it is feasible to shorten the duration of treatment of previously untreated patients with HCV genotype 1 infection with ledipasvir-sofosbuvir from 12 weeks to 8 weeks in the real-world clinical setting,” said Kris Kowdley, MD, of the Swedish Medical Center in Seattle, Washington, at a presentation at Digestive Disease...

Read more...

Source Source: MD Magazine